Wave Life Sciences reports positive Phase 1 INLIGHT data: WVE-007 reduces visceral fat 9.4%, preserves lean mass

Wave Life Sciences Ltd.

Single 240 mg WVE-007 dose: 9.4% visceral fat loss (p=0.02), 4.5% total fat reduction, 3.2% lean mass gain at 3 months.
Serum Activin E suppressed up to 78%; durable reductions support once or twice-yearly dosing.
No severe TEAEs, no discontinuations, no clinically meaningful changes in lipids or liver function.
Phase 2 planning for monotherapy, add-on to incretins, and maintenance post-incretin therapy.
Next data: Q1 2026 6-month follow-up from 240 mg cohort and 3-month from 400 mg cohort.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.